Drug Profile

CYP 002

Alternative Names: CYP-002

Latest Information Update: 28 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cynata Therapeutics
Class Induced pluripotent stem cell therapies; Mesenchymal stem cell therapies; Stem cell therapies; Vascular disorder therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Chronic limb-threatening ischemia

Most Recent Events

28 Sep 2022 No recent reports of development identified for preclinical development in Chronic limb threatening ischemia in Australia (Parenteral)
11 Mar 2020 Cynata Therapeutics receives Notice of Allowance for its MSC technology in Israel and Japan
11 Mar 2020 Cynata Therapeutics has patent protection for its MSC technology in Canada

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com